Figure 6: MET amplification arises in xenograft models of acquired resistance to rociletinib. | Nature Communications

Figure 6: MET amplification arises in xenograft models of acquired resistance to rociletinib.

From: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Figure 6

(a,b) Mice bearing PC-9 NSCLC xenograft tumours (Ex19Del) were treated with the compounds, doses and schedules indicated (n=10 per group). Each line represents an individual animal. On day 60 the erlotinib-treated cohort was split into 2 groups and 3 animals continued on erlotinib while the rest (n=7) were crossed-over to rociletinib. The mean tumour volume in erlotinib monotherapy, erlotinib crossover, and rociletinib monotherapy treated animals was compared using the Wilcoxon rank-sum test. (c,d) Next-generation sequencing was used to assess (c) Ex19Del and T790M allele frequencies and (d) EGFR/MET copy number in the tumours collected at endpoint from mice in the vehicle (n=3), erlotinib resistant (n=3) and rociletinib-resistant (n=4) groups.

Back to article page